viewTiziana Life Sciences PLC

Tiziana Life Sciences to present at BIO CEO & Investor online conference

Earlier this month, the company released data from clinical trials of its nasally-delivered monoclonal antibody in people affected by the coronavirus

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it is presenting at the BIO CEO & Investor Digital Conference.

The conference starts today and runs until Thursday.

Chief executive Dr Kunwar Shailubhai said: “I look forward to sharing our exciting story with conference attendees.

“With the release of our topline data from our COVID-19 trial, multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases in the longer-term, we are well positioned to achieve a series of important milestones in the months and quarters ahead.”

At the start of the month, the company released data from clinical trials of its nasally-delivered monoclonal antibody in people affected by coronavirus.

There was a significant improvement in lung function in the groups of patients receiving the drug, as well as major reductions in Interleukin-6 and c-reactive protein, which are both indicative of inflammation.

Tiziana’s Foralumab was administered on its own and with dexamethasone, a corticosteroid, and the results were compared with a control group.

The fully human anti-CD3 monoclonal antibody (mAB) proved to be safe in the group of 39 patients that were assessed by a team that included researchers from the prestigious Harvard Medical School.

Quick facts: Tiziana Life Sciences PLC

Price: 100 GBX

Market: LSE
Market Cap: £194.61 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...



Tiziana Life Sciences reports strong topline data from Foralumab COVID-19 trial

Tiziana Life Sciences PLC's (NASDAQ:TLSA) (LON:TILS) Dr Kunwar Shailubhai discusses with Proactive's Andrew Scott the positive data from its clinical study of nasally administered Foralumab in COVID-19 patients in Brazil. He says CT scans of the lungs showed the improvement was approximately...

on 2/2/21

2 min read